- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | MEDTIDE Fails to Timely Disclose California Production Facility Construction Contract with Maximum Guaranteed Price of USD22.725M | 1 | AASTOCKS | ||
| Di | MEDTIDE (03880): DISCLOSEABLE TRANSACTION IN RELATION TO THE CONSTRUCTION OF ROCKLIN SITE | - | HKEx | ||
| 27.05. | MEDTIDE (03880): FORM OF PROXY FOR THE 2025 ANNUAL GENERAL MEETING TO BE HELD ON THURSDAY, JUNE 18, 2026 | 1 | HKEx | ||
| 27.05. | MEDTIDE (03880): NOTICE OF THE 2025 ANNUAL GENERAL MEETING | 2 | HKEx | ||
| 27.05. | MEDTIDE (03880): 2025 AGM CIRCULAR | 2 | HKEx | ||
| 16.05. | Hmedium: Medtide Inc. Honored with 2026 Forbes China Industry Development Leading Enterprise Award | 1.011 | Newsfile | Shanghai, China--(Newsfile Corp. - May 15, 2026) - On March 18, 2026, Frost & Sullivan and Forbes China Group jointly hosted the 2026 Forbes China Pioneer Innovators in Industry Development Selection... ► Artikel lesen | |
| MEDTIDE Aktie jetzt für 0€ handeln | |||||
| 23.04. | MEDTIDE (03880): 2025 ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT | - | HKEx | ||
| 23.04. | MEDTIDE (03880): 2025 ANNUAL REPORT | - | HKEx | ||
| 30.03. | MEDTIDE (03880): PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION OF THE COMPANY AND ABOLISHMENT OF THE SUPERVISORY COMMITTEE | 1 | HKEx | ||
| 30.03. | MEDTIDE (03880): ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2025 | - | HKEx | ||
| 16.03. | MEDTIDE (03880): DATE OF BOARD MEETING | - | HKEx | ||
| 09.03. | MEDTIDE (03880): NEXT DAY DISCLOSURE RETURN | 2 | HKEx | ||
| 09.03. | MEDTIDE (03880): INSIDE INFORMATION COMPLETION OF THE H SHARE FULL CIRCULATION | - | HKEx | ||
| 26.02. | MEDTIDE (03880): POSITIVE PROFIT ALERT | 2 | HKEx | ||
| 05.02. | MEDTIDE (03880): INSIDE INFORMATION ISSUANCE OF FILING NOTICE BY CSRC FOR THE H SHARE FULL CIRCULATION APPLICATION OF THE COMPANY | - | HKEx | ||
| 16.07.25 | XFRA NEW INSTRUMENTS AVAILABLE ON 16.07.2025 | 799 | Xetra Newsboard | The following instruments on XETRA do have their first trading 16.07.2025 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 16.07.2025
Aktien
1 CA0589451065 Banco Bilbao Vizcaya... ► Artikel lesen |
16 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 32,070 | -0,60 % | Qiagen-Aktie: Schlafender Riese und Übernahme-Kandidat? | Nach kurstechnisch harten Monaten kämpft sich die Aktie des niederländischen Biotechnologie- und Diagnostikunternehmens Qiagen langsam zurück. Mit Kursen um 32 Euro notiert das Papier noch immer mehr... ► Artikel lesen | |
| PROPANC BIOPHARMA | 2,800 | +107,41 % | Morning Market Movers: Galaxy Payroll, Propanc Biopharma, Big Tree Cloud, VS MEDIA See Big Swings | REDWOOD SHORES (dpa-AFX) - At 8:05 a.m. ET on Thursday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the... ► Artikel lesen | |
| ENLIVEN THERAPEUTICS | 40,640 | +9,84 % | Enliven Therapeutics, Inc.: Enliven Therapeutics Announces Updated Positive Phase 1 Clinical Data and Alignment with FDA on Key Phase 3 Trial Design Components | 61% overall MMR and 48% MMR achievement by 24 weeks in the 80 mg QD Phase 1b cohort
67% overall MMR and 55% MMR achievement by 24 weeks in all Phase 1b patients... ► Artikel lesen | |
| TANGO THERAPEUTICS | 28,620 | -0,21 % | Starke Studiendaten: Nach 626% Kursplus in einem Jahr: Dieser Krebsspezialist macht Anleger sprachlos | © Foto: Bernd Weißbrod/dpa Ein Wirkstoff gegen die tödlichste Form von Bauchspeicheldrüsenkrebs zeigt Daten, die selbst erfahrene Onkologen aufhorchen lassen. Die Aktie reagierte entsprechend.Pankreas-Karzinom... ► Artikel lesen | |
| ADIAL PHARMACEUTICALS | 2,810 | +30,09 % | Adial Pharmaceuticals, Inc.: Adial Pharmaceuticals Announces Acquisition of Azora Therapeutics and up to $64 Million Financing | - Acquisition of Azora and concurrent private placement positions the combined company to advance its pipeline through key clinical milestones in ulcerative colitis, including Phase 1 initiation in... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 13,340 | +2,22 % | Summit Therapeutics withdraws proposed securities offering citing market conditions | ||
| COGENT BIOSCIENCES | 32,450 | +3,41 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Detailed Clinical Data from PEAK Phase 3 Trial with Bezuclastinib in Combination with Sunitinib in Gastrointestinal Stromal Tumors (GIST) at 2026 American Society of Clinical Oncology (ASCO) ... | Bezuclastinib combination is first treatment ever to demonstrate statistically significant advantage against active comparator in GIST patients; median PFS of 16.5 months versus 9.2 months (HR=0.50... ► Artikel lesen | |
| ERASCA | 13,620 | +1,87 % | Erasca, Inc.: Erasca Reports First Quarter 2026 Business Updates and Financial Results | Robust monotherapy efficacy and generally well-tolerated safety results observed during dose escalation for ERAS-0015 in both KRAS G12X NSCLC and PDAC reinforce best-in-class potential across RAS-targeted... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 24,965 | +7,47 % | Arcutis Biotherapeutics, Inc. - 8-K, Current Report | ||
| RECURSION PHARMACEUTICALS | 3,040 | 0,00 % | Recursion Pharmaceuticals: Recursion Reports First Quarter Financial Results and Provides Business Update | Multiple milestones achieved or on track across wholly owned and partnered programs REC-1245 (RBM39 degrader): Early clinical data in solid tumors demonstrate a well-tolerated safety profile and predictable... ► Artikel lesen | |
| NURIX THERAPEUTICS | 16,460 | +7,58 % | Roche geht 2,3-Milliarden-Dollar-Deal mit Nurix für Blutkrebsmittel ein | DJ Roche geht 2,3-Milliarden-Dollar-Deal mit Nurix für Blutkrebsmittel ein
Von Nina Kienle
DOW JONES--Roche hat mit dem US-Biotechunternehmen Nurix Therapeutics eine exklusive Lizenz- und Kooperationsvereinbarung... ► Artikel lesen | |
| IMMUNOVANT | 32,560 | +4,43 % | Immunovant Inc.: Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 | IMVT-1402 showed clinically meaningful response rates of 72.7% ACR20, 54.5% ACR50 and 35.8% ACR70 at Week 16 in the open label period of its trial in difficult-to-treat rheumatoid arthritis (D2T RA)... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 248,67 | +3,33 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Provides Vormatrigine Program Update | POWER1 Study in highly refractory patients with focal onset seizures did not meet its primary success measure Secondary measure, the 50% response rate, was met and seizure reduction during the second... ► Artikel lesen | |
| ADMA BIOLOGICS | 8,460 | -0,24 % | Kehoe Law Firm, P.C.: ADMA Biologics Stock Alert (ADMA) - Kehoe Law Firm, P.C. Investigating Potential Securities Claims on Behalf of ADMA Biologics Investors | Philadelphia, Pennsylvania--(Newsfile Corp. - May 7, 2026) - Kehoe Law Firm, P.C. is investigating potential securities claims on behalf of investors of ADMA Biologics, Inc. ("ADMA Biologics" or... ► Artikel lesen | |
| IMMUNOME | 18,330 | +0,94 % | Immunome doses first patient in IM-1617 cancer therapy trial |
Das Unternehmen MEDTIDE INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von +0,100 (+4,63 %) liegt der Kurs bei 2,260 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MEDTIDE INC finden Sie auf Wallstreet Online.